Article
Imatinib mesylate in thymic epithelial malignancies.
Cancer chemotherapy and pharmacology - 1 Feb 2012
Palmieri Giovannella, Marino Mirella, Buonerba Carlo, Federico Piera, Conti Salvatore, Milella Michele, Petillo Luigi, Evoli Amelia, Lalle Maurizio, Ceribelli Anna, Merola Gerardina, Matano Elide, Sioletic Stefano, De Placido Sabino, Di Lorenzo Giuseppe, Damiano Vincenzo
Abstract excerpt
PURPOSE: Thymic epithelial tumors (TETs) are rare tumors of the mediastinum, with an estimated incidence of about 3 cases per 100,000 inhabitants. Although anthracycline- and platinum-based chemotherapy is an active treatment for TETs, novel systemic therapeutic options are especially needed for metastatic disease, which is virtually incurable. On the basis of the radiographic response obtained with imatinib...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.